Abstract:Abstract Background: Sarcoma is a malignant cancer that arises from transformed cells of mesenchymal origin. Sarcoma has the characteristics of low incidence and wide distribution of onset age. Sarcoma patients have poor prognosis and very limited selection of approved targeted drugs. Till now, the genomic features of sarcoma patients in China have not been well understood. Here we present the comprehensive genomic features of 202 sarcoma patients and compared mutations in different subtypes of sarcomas. Methods: Deep sequencing targeting 450 cancer genes was performed on FFPE and matched blood samples collected from 202 sarcoma patients. Based on the histology patients included 33 osteosarcoma (OS), 24 rhabdomyosarcoma (RMS), 20 liposarcoma (LPS), 19 fibrosarcoma (FBS), 16 leiomyosarcoma (LMS), 14 Ewing’s sarcoma (ES), 11 hemangiosarcoma (HMS), 10 synovial sarcoma (SS), 9 chondrosarcoma (CDS), and 46 others in this study. Genomic alterations (GAs) including single nucleotide variants (SNVs), insertions and deletions, copy number variations (CNV) and fusions were assessed. Results: Based on the deep sequencing results, there are 1219 somatic mutations detected in all 202 sarcomas, average 6.0 mutations per sample. The most common GAs of LPS, ES and SS’s are consistent with those mentioned in NCCN guidelines (MDM2 55%, EWSR1 78.6% and SS18 80%, respectively). OS, RMS and LMS shared the same most common GAs of TP53 (25%-50%). The second ranked common GAs were NCOR1 (24%), FRS2 (20.8%), ATRX (25%) genes, and the third ranked GAs were RB1 (24%), CDK4 (16.7%) and MAP2K4 (25%) genes. 161/202 patients (79.7%) harbored at least one actionable mutations which might benefit from FDA approved drugs or drugs were under investigation in clinical trials. All FBS, 93.8% LMS and 90.9% HMS have actionable mutations, however, only 10% SS and 35.7% ES have actionable mutations. 8 samples have CNV (including MDM2/4, EGFR and CCND1) which was related to hyper-progression of immunotherapy. All these 8 samples were bone tumor including 4 OS, 1 CDS, 2 ES and 1 fibrosarcoma of bone. Conclusions: Through the comprehensive genomic profiling, different types of sarcomas showed different characteristics of genomic alterations, and potential therapeutic targets may be identified for the patients. Further, NGS provides information on whether or not patients may have the potential hyper-progression of immunotherapy. Citation Format: Xinghua Song, Zuping Lian, YanBin Xiao, Kunpeng Bu, Ye Qiu, Tao Ji, Dan Liu, Angen Liu, Kai Wang. Comparison of mutations in different subtypes of sarcomas and its clinical implications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3421.

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis

Molecular profile of bladder cancer progression to clinically aggressive subtypes

TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma

Aggressive muscle-invasive bladder cancer with sarcomatoid differentiation in a 10-year-old girl: A case report

Abstract 3421: Comparison of Mutations in Different Subtypes of Sarcomas and Its Clinical Implications

Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2

Sarcomatoid Carcinoma of the Urinary Bladder: A Case Report

Describing the genomic landscape of bladder cancer histologic subtypes.

RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma

Abstract 7040: Mutations in cytoskeleton genes SPTAN1/SPTBN1 serve as novel predictive markers for immunotherapy against bladder cancer

Integration of ubiquitination-related genes in predictive signatures for prognosis and immunotherapy response in sarcoma

ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity

Single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma

Integrated Molecular Characterization of Uterine Carcinosarcoma

Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

Plasmacytoid urothelial carcinoma of the urinary bladder–A clinicopathological and molecular analysis of 52 cases

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung

Supplementary Tables S1-6 and S8 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma.